RBC Capital lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $541 from $546 and keeps an Outperform rating on the shares. With no pove data yet, the company posted a somewhat anticlimactic quarter, though solid sales and generally in-line guidance should maintain favorable perceptions around the health and durability of their core franchises, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $577 from $572 at Bernstein
- Crispr Therapeutics price target raised to $74 from $62 at Evercore ISI
- Vertex Pharmaceuticals price target raised to $590 from $485 at Cantor Fitzgerald
- Balancing Solid CF Revenue With Kidney Pipeline Uncertainty: Why Stringer Maintains a Hold on Vertex
- Vertex Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer